JP2023538098A5 - - Google Patents

Info

Publication number
JP2023538098A5
JP2023538098A5 JP2023512280A JP2023512280A JP2023538098A5 JP 2023538098 A5 JP2023538098 A5 JP 2023538098A5 JP 2023512280 A JP2023512280 A JP 2023512280A JP 2023512280 A JP2023512280 A JP 2023512280A JP 2023538098 A5 JP2023538098 A5 JP 2023538098A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cdr
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023512280A
Other languages
English (en)
Japanese (ja)
Other versions
JP7858629B2 (ja
JP2023538098A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/046958 external-priority patent/WO2022040560A1/en
Publication of JP2023538098A publication Critical patent/JP2023538098A/ja
Publication of JP2023538098A5 publication Critical patent/JP2023538098A5/ja
Priority to JP2026074915A priority Critical patent/JP2026126325A/ja
Application granted granted Critical
Publication of JP7858629B2 publication Critical patent/JP7858629B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023512280A 2020-08-21 2021-08-20 Fgfr3抗体および使用の方法 Active JP7858629B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026074915A JP2026126325A (ja) 2020-08-21 2026-04-28 Fgfr3抗体および使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063068575P 2020-08-21 2020-08-21
US63/068,575 2020-08-21
PCT/US2021/046958 WO2022040560A1 (en) 2020-08-21 2021-08-20 Fgfr3 antibodies and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026074915A Division JP2026126325A (ja) 2020-08-21 2026-04-28 Fgfr3抗体および使用の方法

Publications (3)

Publication Number Publication Date
JP2023538098A JP2023538098A (ja) 2023-09-06
JP2023538098A5 true JP2023538098A5 (cg-RX-API-DMAC10.html) 2024-08-27
JP7858629B2 JP7858629B2 (ja) 2026-05-14

Family

ID=77774991

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023512280A Active JP7858629B2 (ja) 2020-08-21 2021-08-20 Fgfr3抗体および使用の方法
JP2026074915A Pending JP2026126325A (ja) 2020-08-21 2026-04-28 Fgfr3抗体および使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026074915A Pending JP2026126325A (ja) 2020-08-21 2026-04-28 Fgfr3抗体および使用の方法

Country Status (14)

Country Link
US (2) US11505611B2 (cg-RX-API-DMAC10.html)
EP (1) EP4200019A1 (cg-RX-API-DMAC10.html)
JP (2) JP7858629B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230052963A (cg-RX-API-DMAC10.html)
CN (1) CN116323666A (cg-RX-API-DMAC10.html)
AR (1) AR123306A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021327387A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023002455A2 (cg-RX-API-DMAC10.html)
CA (1) CA3189470A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023001559A2 (cg-RX-API-DMAC10.html)
IL (1) IL300623A (cg-RX-API-DMAC10.html)
MX (1) MX2023002106A (cg-RX-API-DMAC10.html)
TW (1) TW202229343A (cg-RX-API-DMAC10.html)
WO (1) WO2022040560A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
CN120456916A (zh) * 2022-11-14 2025-08-08 瑞泽恩制药公司 抗fgfr3抗体和抗原结合片段及其使用方法
CN121002062A (zh) 2023-01-13 2025-11-21 再生元制药公司 Fgfr3结合分子及其使用方法
KR20250162619A (ko) 2023-03-20 2025-11-18 아센디스 파마 그로우쓰 디스오더스 에이/에스 연골무형성증을 가진 인간 대상에서의 흉요추 변형의 치료 방법
WO2025207944A1 (en) * 2024-03-29 2025-10-02 Sidewinder Therapeutics, Inc. Fgfr3-iiib-binding antibodies
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000916A2 (en) 1989-07-06 1991-01-24 The Regents Of The University Of California Receptors for fibroblast growth factors
DK0646182T3 (da) 1992-06-18 1996-09-16 Whittier Inst Diabetes & Endoc Fremgangsmåde til påvisning af neoplastiske sygdomme
AU6446194A (en) 1993-03-17 1994-10-11 Whittier Institute For Diabetes And Endocrinology, The Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof
US6517872B1 (en) 1995-06-12 2003-02-11 Yeda Research And Development Co., Ltd. FGFR3 as a marker for mesenchymal skeletal progenitor cells
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US20030143676A1 (en) 1999-03-25 2003-07-31 Genesis Research And Development Corporation Limited Fibroblast growth factor receptors and methods for their use
EP1208231B2 (en) 1999-05-05 2009-12-30 Institut Curie Means for detecting and treating pathologies linked to fgfr3
US7135311B1 (en) 1999-05-05 2006-11-14 Institut Curie Means for detecting and treating pathologies linked to FGFR3
AU7764200A (en) 1999-10-06 2001-05-10 Tigenix N.V. In vivo assay and molecular markers for testing the phenotypic stability of cellpopulations, and selecting cell populations for autologous transplantation
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
ES2363765T3 (es) 2002-01-31 2011-08-16 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Agonistas de fgfr.
NZ537208A (en) 2002-06-27 2009-02-28 Adipogen Pharmaceuticals Pty Ltd Differentiation modulating agents and uses therefor
AU2003265057A1 (en) 2002-09-04 2004-03-29 Abtech Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
CA2510715A1 (en) 2002-12-20 2004-07-08 Enkam Pharmaceuticals A/S Method of modulation of interaction between receptor and ligand
WO2004074506A2 (en) 2003-02-13 2004-09-02 Mergen Ltd Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
US8124331B2 (en) 2003-03-26 2012-02-28 Progenika Biopharma, S.A. In vitro method to detect bladder transitional cell carcinoma
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
WO2005066211A2 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
EP1544213B1 (en) 2003-12-19 2008-02-20 Charité - Universitätsmedizin Berlin Use of ligands of the antigen cd52 for the treatment of solid tumours and bone-related cancerous diseases
AU2005216547B2 (en) 2004-02-24 2009-03-12 Allergan, Inc. Botulinum toxin screening assays
EP1773305A2 (en) 2004-05-25 2007-04-18 Yale University Corporation Method for treating skeletal disorders resulting from fgfr malfunction
AU2005302083A1 (en) 2004-11-04 2006-05-11 Fibron Limited Treatment of B-cell malignancies
EP1659175A1 (en) 2004-11-18 2006-05-24 Institut Curie Alterations in seborrheic keratoses and their applications
ATE423140T1 (de) 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
EP1861419B1 (en) 2005-03-15 2011-06-29 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP2009511613A (ja) 2005-10-17 2009-03-19 エンカム ファーマシューティカルズ アクティーゼルスカブ 神経細胞接着分子l1のペプチド断片を含む新規fgf受容体結合化合物
WO2007067968A2 (en) 2005-12-08 2007-06-14 Novartis Ag Effects of inhibitors of fgfr3 on gene transcription
US8101721B2 (en) 2006-06-15 2012-01-24 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
WO2008127707A1 (en) 2007-04-13 2008-10-23 Dana Farber Cancer Institute, Inc. Receptor tyrosine kinase profiling
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
ES2553390T3 (es) 2008-02-25 2015-12-09 Nestec S.A. Método para la detección de receptores truncados intracelulares
WO2009146033A2 (en) 2008-03-31 2009-12-03 Sma Foundation Compositions and methods for modulating smn activity
KR101590495B1 (ko) 2008-05-29 2016-02-01 갤럭시 바이오테크, 엘엘씨 염기성 섬유모세포 성장 인자에 대한 모노클로날 항체
WO2010002862A2 (en) 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
AR073770A1 (es) 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
ES2549769T3 (es) 2009-03-25 2015-11-02 Genentech, Inc. Anticuerpos anti-FGFR3 y métodos que emplean los mismos
WO2011088196A2 (en) 2010-01-14 2011-07-21 Yale University Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
KR20220017512A (ko) 2012-03-08 2022-02-11 아스테라스 세이야쿠 가부시키가이샤 신규 fgfr3 융합체
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US20150292030A1 (en) 2012-11-27 2015-10-15 Board Of Regents, The University Of Texas System Methods of characterizing and treating molecular subset of muscle-invasive bladder cancer
CN105209607B (zh) 2013-04-05 2020-02-07 大学健康网络 产生软骨细胞谱系细胞和/或类软骨组织的方法和组合物
TWI541022B (zh) 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體-3(fgfr3)之化合物及治療方法
SG11201706727XA (en) 2015-02-19 2017-09-28 Bioclin Therapeutics Inc Methods, compositions, and kits for treatment of cancer
CN110785184A (zh) 2017-02-06 2020-02-11 雷尼尔医疗公司 用于治疗癌症的方法,组合物和试剂盒

Similar Documents

Publication Publication Date Title
JP2020517249A5 (cg-RX-API-DMAC10.html)
US11827701B2 (en) IL-6 binding molecules
TW202126694A (zh) 標靶cd3的抗體、雙特異性抗體及其用途
JP6647208B2 (ja) 抗il−17抗体、その生産および使用のための方法
JP2018108081A5 (cg-RX-API-DMAC10.html)
JP2019527194A5 (cg-RX-API-DMAC10.html)
RU2012112829A (ru) Анти-gitr-антитела
JP2018510617A5 (cg-RX-API-DMAC10.html)
RU2019140602A (ru) АНТИ-GARP-TGF-β-АНТИТЕЛА
TWI797609B (zh) 抗pd-1和pd-l1的四價雙特異性抗體
JP2013519364A5 (cg-RX-API-DMAC10.html)
RU2009110154A (ru) АНТИТЕЛА ПРОТИВ C5aR С УЛУЧШЕННЫМИ СВОЙСТВАМИ
WO2021219046A1 (zh) 靶向her2的抗原结合构建体及用途
TW202613163A (zh) 一種雙特異性抗體及其應用
CN116323666A (zh) Fgfr3抗体和使用方法
JP2025541367A (ja) 多価および多重特異性サイトカインアンタゴニスト
CN104045713B (zh) 一种抗Blys的单克隆抗体及含有该抗体的药物组合物
CN115746144B (zh) 抗tigit-pd1双特异性抗体及其应用
WO2024046305A1 (zh) 免疫调节剂的筛选和制备方法
JP2025517120A5 (cg-RX-API-DMAC10.html)
CN116528909A (zh) 抗肿瘤坏死因子受体(tnfr2)抗体及其用途
WO2019174637A1 (zh) 一种针对tim-3的全人源化抗体分子、抗原结合片段及其医药用途
CN115151572A (zh) 针对ror1的抗体及其用途
CN116003620A (zh) 一种结合PD-1和Siglec15的双特异性抗体
KR20250069411A (ko) 항 ceacam5 항체 및 이의 용도